Liquid Torem 60mL 60mgs/mL

Toremifene (Torem) is a drug in a class called “selective estrogen receptor modulators” or SERM’s for short. A SERM has selective estrogen receptor binding abilities and will help oppose the actions of estrogen at the binding receptors Torem effects (breast glands for example). This has led to Torem being researched in the treatment of breast cancer, prostate cancer, Gynecomastia and to treat some side effects related to androgen deprivation therapy, like osteoporosis. Torem has a very good oral availability and has been shown in research to be very effective at causing an increase in follicle-stimulating hormone (FSH) and testosterone levels. Torem has also shown a very positive effect on sperm concentration, mobility and quality in male research subjects. This is of interest to researchers because all these things play a big role in fertility and with Torem we can now further research into infertility and possible treatments for this condition. Ref: 1) Emerging therapies to prevent skeletal morbidity in men with prostate cancer.Saylor PJ, Lee RJ, Smith MR. http://www.ncbi.nlm.nih.gov/pubmed/21860001 2) Management of osteoporosis in men on androgen deprivation therapy.Adler RA. http://www.ncbi.nlm.nih.gov/pubmed/21129866 3) Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithelial cells.Nomura H, Kawashima H, Masaki S, Hosono TY, Matsumura K, Tamada S, Tanaka T, Nakatani T. http://www.ncbi.nlm.nih.gov/pubmed/19468285 4) The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia.Tsourdi E, Kourtis A, Farmakiotis D, Katsikis I, Salmas M, Panidis D. http://www.ncbi.nlm.nih.gov/pubmed/18692782 5) Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study.Smith MR, Malkowicz SB, Chu F, Forrest J, Sieber P, Barnette KG, Rodriquez D, Steiner MS. http://www.ncbi.nlm.nih.gov/pubmed/18398147 6) The beneficial effects of toremifene administration on the hypothalamic-pituitary-testicular axis and sperm parameters in men with idiopathic oligozoospermia.Farmakiotis D, Farmakis C, Rousso D, Kourtis A, Katsikis I, Panidis D. http://www.ncbi.nlm.nih.gov/pubmed/17412336 7) Treatment-related osteoporosis in men with prostate cancer.Smith MR. http://www.ncbi.nlm.nih.gov/pubmed/17062721